Latest Comments

Majority of UC Cases Considered Mild to Moderate

Majority of UC Cases Considered Mild to Moderate

New Data Released for Roche’s Latest Game-Changing Drug for Multiple Sclerosis

New Data Released for Roche’s Latest Game-Changing Drug for Multiple Sclerosis

Carcinoma Remains Predominant Histologic Subtype of Ovarian Cancer

Carcinoma Remains Predominant Histologic Subtype of Ovarian Cancer

EMA withdrawal threatens UK patient access to cutting edge therapies

EMA withdrawal threatens UK patient access to cutting edge therapies

Improved and affordable diagnostics for kidney transplant rejection

Improved and affordable diagnostics for kidney transplant rejection

Unmet needs in melanoma treatment

Unmet needs in melanoma treatment

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention

Verily aims to become a prophet of human health

Verily aims to become a prophet of human health

Where you live matters: geographic differences in DAA treatment access

Where you live matters: geographic differences in DAA treatment access

Quality-of-life improvements: DAA treatment from the patient’s perspective

Quality-of-life improvements: DAA treatment from the patient’s perspective

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

CRISPR: are genetic mutants the future of disease treatment?

CRISPR: are genetic mutants the future of disease treatment?

Hope for sufferers with extremely rare form of liver cancer

Hope for sufferers with extremely rare form of liver cancer

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

AD/PD conference coverage: How to succeed in late-phase Alzheimer’s research

AD/PD conference coverage: How to succeed in late-phase Alzheimer’s research

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

New class of diabetes drugs show heart failure prevention signal

New class of diabetes drugs show heart failure prevention signal

Positive results from the long-term extension of Nemolizumab in atopic dermatitis

Positive results from the long-term extension of Nemolizumab in atopic dermatitis

Encouraging interim safety data on long-term use of Xeljanz in psoriatic arthritis

Encouraging interim safety data on long-term use of Xeljanz in psoriatic arthritis

Tapinarof poised to fill a void in psoriasis treatment

Tapinarof poised to fill a void in psoriasis treatment

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data